Curasight Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer
· Recruitment of first patient triggers second milestone payment of USD 500.000 to Curasight under the collaboration agreement for uTRACE[®] in prostate cancer with Curium Inc. · Milestone is an important step in the development of the uTRACE PET imaging technology, part of Curasight’s theranostic platform leveraging the uPAR target for improved diagnosis (uTRACE[®]) and radioligand treatment (uTREAT[®]) of certain cancers · Under the agreement signed with Curium Inc. in 2023, Curasight is eligible to receive up to mUSD 70 in development and commercial milestones plus double-digit